作者: N Kapp , D Grossman , E Jackson , L Castleman , D Brahmi
关键词:
摘要: Given the overall safety profile and increasing availability of medical pregnancy termination drugs, we asked: would mifepristone-misoprostol regimen for at ≤10 weeks gestation meet U.S. FDA regulatory criteria over-the-counter (OTC) approval, if not, what are present research gaps? We conducted a literature review consumer behaviors necessary successful OTC application identified crucial gaps. If were to embark on development program or more generally, self-use termination, critical elements missing label comprehension, self –selection actual use studies. This article is protected by copyright. All rights reserved.